A220100 Stock Overview
Engages in the research and development, production, and sale of radiopharmaceuticals in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Risk Analysis
No risks detected for A220100 from our risk checks.
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
FutureChem Co.,Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩18,430.00 |
| 52 Week High | ₩31,250.00 |
| 52 Week Low | ₩11,660.00 |
| Beta | 1.38 |
| 1 Month Change | -18.09% |
| 3 Month Change | -8.76% |
| 1 Year Change | 39.83% |
| 3 Year Change | 34.22% |
| 5 Year Change | 155.56% |
| Change since IPO | 160.19% |
Recent News & Updates
There's Reason For Concern Over FutureChem Co.,Ltd's (KOSDAQ:220100) Massive 33% Price Jump
Feb 07
Does FutureChemLtd (KOSDAQ:220100) Have A Healthy Balance Sheet?
Dec 20More Unpleasant Surprises Could Be In Store For FutureChem Co.,Ltd's (KOSDAQ:220100) Shares After Tumbling 27%
Nov 12Recent updates
There's Reason For Concern Over FutureChem Co.,Ltd's (KOSDAQ:220100) Massive 33% Price Jump
Feb 07Does FutureChemLtd (KOSDAQ:220100) Have A Healthy Balance Sheet?
Dec 20More Unpleasant Surprises Could Be In Store For FutureChem Co.,Ltd's (KOSDAQ:220100) Shares After Tumbling 27%
Nov 12FutureChem Co.,Ltd's (KOSDAQ:220100) 29% Share Price Surge Not Quite Adding Up
Sep 04FutureChemLtd (KOSDAQ:220100) Is In A Good Position To Deliver On Growth Plans
Jun 13FutureChem Co.,Ltd (KOSDAQ:220100) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected
Apr 29Revenues Not Telling The Story For FutureChem Co.,Ltd (KOSDAQ:220100)
Feb 26Is FutureChemLtd (KOSDAQ:220100) Using Debt In A Risky Way?
Feb 05
What Percentage Of FutureChem Co.,Ltd (KOSDAQ:220100) Shares Do Insiders Own?
Dec 14Shareholder Returns
| A220100 | KR Life Sciences | KR Market | |
|---|---|---|---|
| 7D | -2.3% | -3.1% | 2.1% |
| 1Y | 39.8% | 37.9% | -7.6% |
Return vs Industry: A220100 exceeded the KR Life Sciences industry which returned 37.9% over the past year.
Return vs Market: A220100 exceeded the KR Market which returned -7.6% over the past year.
Price Volatility
| A220100 volatility | |
|---|---|
| A220100 Average Weekly Movement | 8.6% |
| Life Sciences Industry Average Movement | 5.3% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in KR Market | 12.6% |
| 10% least volatile stocks in KR Market | 2.9% |
Stable Share Price: A220100 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A220100's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 66 | Dae-Yoon Chi | www.futurechem.co.kr |
FutureChem Co.,Ltd engages in the research and development, production, and sale of radiopharmaceuticals in South Korea. The company offers PDVUE, a positron emission tomography (PET) radiopharmaceutical diagnostic medicine for Parkinson’s disease; Alzavue, a radiopharmaceutical for Aalzheimer's disease; and [18F]FDG, a PET radiopharmaceutical for the treatment of cancer. Its products in pipeline include 18F-FC303 and 177Lu-FC705 for the treatment of prostate cancer; 18F-FMT for the treatment of brain tumor; 18F-FC505, for the treatment of atherosclerotic plaque; and 18F-FC211, for the treatment of Alzheimer’s disease.
FutureChem Co.,Ltd Fundamentals Summary
| A220100 fundamental statistics | |
|---|---|
| Market cap | ₩407.25b |
| Earnings (TTM) | -₩9.42b |
| Revenue (TTM) | ₩17.29b |
23.5x
P/S Ratio-43.2x
P/E RatioIs A220100 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A220100 income statement (TTM) | |
|---|---|
| Revenue | ₩17.29b |
| Cost of Revenue | ₩14.27b |
| Gross Profit | ₩3.02b |
| Other Expenses | ₩12.44b |
| Earnings | -₩9.42b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -426.19 |
| Gross Margin | 17.49% |
| Net Profit Margin | -54.46% |
| Debt/Equity Ratio | 1.9% |
How did A220100 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/29 22:17 |
| End of Day Share Price | 2025/04/29 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
FutureChem Co.,Ltd is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Wan Ku | NH Investment & Securities Co., Ltd. |
| Minyong Eom | Shinhan Investment Corp. |